BBRP11041

BBRP11041 is a small molecule drug developed by Benobio for the treatment of osteoarthritis. It is currently in Phase 1 clinical development. The drug targets diseases of the immune system and musculoskeletal system, with its primary indication being osteoarthritis. Specific details about its mechanism of action have not been disclosed publicly as of June 2025, but it is distinct from other Benobio pipeline molecules such as BBC0901 (a BRD4 inhibitor). The available data confirm that BBRP11041 is an investigational agent under early-stage clinical evaluation for intra-articular or systemic use in osteoarthritis[1][3].